Genmab AS Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Genmab AS Stock Summary

Genmab AS competes with Ascendis Pharma, Apellis Pharmaceuticals, Akero Therapeutics, Blueprint Medicines, and Day One. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States.

Genmab AS Key Financial Ratios

Genmab AS Key Balance Sheet Accounts

Genmab AS Key Income Statement Accounts

Genmab AS Key Cash Accounts

Genmab Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Genmab AS's current stock value. Our valuation model uses many indicators to compare Genmab AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genmab AS competition to find correlations between indicators driving Genmab AS's intrinsic value. More Info.Genmab AS is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about  0.47  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genmab AS is roughly  2.11 . At present, Genmab AS's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genmab AS's earnings, one of the primary drivers of an investment's value.

Genmab AS Systematic Risk

Today, most investors in Genmab AS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genmab AS's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Genmab AS growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Genmab AS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genmab AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on widely used predictive technical indicators. In general, we focus on analyzing Genmab Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genmab AS's daily price indicators and compare them against related drivers.

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.